enGene Therapeutics Inc. ENGN
2.41 USD +0.13 (+5.70%)
At closeNov 13, 2026, 7:58 PM EST
2.32 -0.09 -3.78%
After hours · Nov 13, 7:58 PM ET
2.17 Day range 2.50
1.44 52-week range 12.17
- YTD
- -73.31%
- 1 year
- -71.41%
News
benzinga.com Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target Leerink Partners analyst Lili Nsongo upgrades enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Outperform and announces $5 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded AMD, Reliance, enGene, Mid Penn Bancorp and Republic Services, raising price targets for RS and MPB.
benzinga.com Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4 Piper Sandler analyst Allison Bratzel upgrades enGene Therapeutics (NASDAQ:ENGN) from Neutral to Overweight and maintains the price target from $4 to $4.
benzinga.com Wells Fargo Upgrades enGene Therapeutics to Overweight, Raises Price Target to $6 Wells Fargo analyst Yanan Zhu upgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Overweight and raises the price target from $2 to $6.
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…
businesswire.com enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the…
businesswire.com enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of…